News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer


5/1/2008 10:13:29 AM

TUCSON, Ariz.--(BUSINESS WIRE)--AmpliMed Corporation, a cancer therapeutics company, today announced that patient enrollment is underway in a Phase 2 trial of Amplimexon® (imexon for injection) in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer. Amplimexon, AmpliMed’s lead product candidate, is a chemotherapeutic that has demonstrated clinical and preclinical activity against a range of tumors. The trial is opening at clinical sites throughout the United States.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES